July 9, 2024 – In direct comparison of the Weight loss Compared to the drugs Mounjaro and Ozempic, Mounjaro was found to be the perfect treatment for helping people shed pounds. It was also more practical in producing significant weight reduction in comparison with Ozempic.
Both medications are intended for individuals who Type 2 diabetesThe latest evaluation also included some individuals who didn’t have the disease but took the drugs as part of what’s often called off-label use.
The findings are based on an evaluation of electronic health records. A record evaluation is a distinct approach than a sometimes preferred but more lengthy research method called a clinical trial, which involves recruiting people for a study in response to very specific criteria to make sure a transparent comparison. But these latest findings from record evaluation are attracting serious attention because they published within the renowned Journal of the American Medical Association JAMA Internal Medicine and are considered the primary direct comparison of the 2 drugs.
The lively ingredient in Mounjaro is tirzepatide, and the manufacturer Eli Lilly also markets tirzepatide under the name Zepbound as a standalone weight reduction drug. The lively ingredient in Ozempic is semaglutide, and Novo Nordisk also makes a weight reduction version called Wegovy. Both tirzepatide and semaglutide belong to the identical class of medicine called GLP-1.
The researchers examined weight changes after people took the drugs for 3, 6 and 12 months. They showed that:
- After 3 months, people taking tirzepatide lost a median of 5.9% of their body weight, compared with 3.6% in people taking semaglutide.
- After 6 months, weight reduction within the tirzepatide group averaged 10.1%, compared with 5.8% for semaglutide.
- After one yr, the typical weight reduction was 15.3% with tirzepatide and eight.3% with semaglutide.
These changes are akin to a 200-pound person losing just over 30 kilos after taking tirzepatide for one yr or simply over 16 kilos after taking semaglutide for one yr.
The results are consistent with the outcomes of previous clinical trials that individually examined weight reduction in people taking the drugs, which indicated that tirzepatide may result in greater weight reduction. Semaglutide was previously shown to support a median weight reduction of roughly 15% of body weight after roughly 1 yr and 4 months, and tirzepatide was related to a median weight reduction of more than 20% after the themes had taken the drug for a couple of yr and almost five months.
For this latest study, researchers analyzed electronic health records of 41,222 adults whose average age was 52 years and their average starting weight was 243 kilos. The study was funded by the private company Truveta Inc.based in Washington State, focuses on the evaluation of electronic patient record data.
All people within the study were considered obese or obese and received either semaglutide or tirzepatide between May 2022 and September 2023.
The researchers also analyzed reports in patients' medical records of gastrointestinal problems, that are common unwanted side effects of the drugs. The frequency of gastrointestinal problems was similar for each drugs.